These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2226 related items for PubMed ID: 28052626

  • 1. Therapies in non-alcoholic steatohepatitis (NASH).
    Oseini AM, Sanyal AJ.
    Liver Int; 2017 Jan; 37 Suppl 1(Suppl 1):97-103. PubMed ID: 28052626
    [Abstract] [Full Text] [Related]

  • 2. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S, Kienbacher C, Halilbasic E, Rechling C, Kazemi-Shirazi L, Hofer H, Munda P, Trauner M.
    Dig Dis; 2015 Jan; 33(4):598-607. PubMed ID: 26159280
    [Abstract] [Full Text] [Related]

  • 3. Current and future pharmacologic treatment of nonalcoholic steatohepatitis.
    Banini BA, Sanyal AJ.
    Curr Opin Gastroenterol; 2017 May; 33(3):134-141. PubMed ID: 28346237
    [Abstract] [Full Text] [Related]

  • 4. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG, Alexandrides TK, Bilianou H, Cholongitas E, Doumas M, Ganotakis ES, Goudevenos J, Elisaf MS, Germanidis G, Giouleme O, Karagiannis A, Karvounis C, Katsiki N, Kotsis V, Kountouras J, Liberopoulos E, Pitsavos C, Polyzos S, Rallidis LS, Richter D, Tsapas AG, Tselepis AD, Tsioufis K, Tziomalos K, Tzotzas T, Vasiliadis TG, Vlachopoulos C, Mikhailidis DP, Mantzoros C.
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [Abstract] [Full Text] [Related]

  • 5. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG, Polyzos SA, Kountouras J, Katsiki N, Anagnostis P, Doumas M, Mantzoros CS.
    Curr Vasc Pharmacol; 2020 Jun; 18(2):172-181. PubMed ID: 30961499
    [Abstract] [Full Text] [Related]

  • 6. Future therapy for non-alcoholic fatty liver disease.
    Issa D, Patel V, Sanyal AJ.
    Liver Int; 2018 Feb; 38 Suppl 1():56-63. PubMed ID: 29427492
    [Abstract] [Full Text] [Related]

  • 7. [Prognosis and treatment of non-alcoholic fatty liver disease and steatohepatitis].
    Heebøll S, Kazankov K, Poulsen MK, Vilstrup H, Grønbæk H.
    Ugeskr Laeger; 2012 Feb 20; 174(8):488-90. PubMed ID: 22348670
    [Abstract] [Full Text] [Related]

  • 8. Current treatment of non-alcoholic fatty liver disease.
    Paternostro R, Trauner M.
    J Intern Med; 2022 Aug 20; 292(2):190-204. PubMed ID: 35796150
    [Abstract] [Full Text] [Related]

  • 9. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
    Cusi K.
    Diabetologia; 2016 Jun 20; 59(6):1112-20. PubMed ID: 27101131
    [Abstract] [Full Text] [Related]

  • 10. The therapeutic landscape of non-alcoholic steatohepatitis.
    Perazzo H, Dufour JF.
    Liver Int; 2017 May 20; 37(5):634-647. PubMed ID: 27727520
    [Abstract] [Full Text] [Related]

  • 11. Nonalcoholic Fatty Liver Disease: Common Questions and Answers on Diagnosis and Management.
    Westfall E, Jeske R, Bader AR.
    Am Fam Physician; 2020 Nov 15; 102(10):603-612. PubMed ID: 33179890
    [Abstract] [Full Text] [Related]

  • 12. Current and future treatment options in non-alcoholic steatohepatitis (NASH).
    Lazaridis N, Tsochatzis E.
    Expert Rev Gastroenterol Hepatol; 2017 Apr 15; 11(4):357-369. PubMed ID: 28276821
    [Abstract] [Full Text] [Related]

  • 13. Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.
    Corey KE, Rinella ME.
    Dig Dis Sci; 2016 May 15; 61(5):1387-97. PubMed ID: 26942734
    [Abstract] [Full Text] [Related]

  • 14. Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis.
    Fang L, Li J, Zeng H, Liu J.
    Prim Care Diabetes; 2024 Jun 15; 18(3):268-276. PubMed ID: 38555202
    [Abstract] [Full Text] [Related]

  • 15. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M, Bukong TN, Csak T, Saha B, Park JK, Ambade A, Kodys K, Szabo G.
    J Transl Med; 2015 Jun 16; 13():193. PubMed ID: 26077675
    [Abstract] [Full Text] [Related]

  • 16. Management and diagnosis of fatty liver disease.
    Schneier AT, Citti CC, Dieterich DT.
    Expert Rev Gastroenterol Hepatol; 2015 May 16; 9(5):671-83. PubMed ID: 25716275
    [Abstract] [Full Text] [Related]

  • 17. Diagnosis and management of non-alcoholic fatty liver disease.
    Jennison E, Patel J, Scorletti E, Byrne CD.
    Postgrad Med J; 2019 Jun 16; 95(1124):314-322. PubMed ID: 31085617
    [Abstract] [Full Text] [Related]

  • 18. Nonalcoholic fatty liver disease: a systematic review.
    Rinella ME.
    JAMA; 2015 Jun 09; 313(22):2263-73. PubMed ID: 26057287
    [Abstract] [Full Text] [Related]

  • 19. Review article: new treatments in non-alcoholic fatty liver disease.
    Townsend SA, Newsome PN.
    Aliment Pharmacol Ther; 2017 Sep 09; 46(5):494-507. PubMed ID: 28677333
    [Abstract] [Full Text] [Related]

  • 20. Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Current Issues and Future Perspectives in Preclinical and Clinical Research.
    Berardo C, Di Pasqua LG, Cagna M, Richelmi P, Vairetti M, Ferrigno A.
    Int J Mol Sci; 2020 Dec 17; 21(24):. PubMed ID: 33348908
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 112.